Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!

About | View Sample | Privacy

Hottest Products

Compare Top Solutions in:

Evaluate more than 400,000 products >>

Featured Jobs

Partner
Lundbeckfond Ventures - Copenhagen, Denmark
Director, IT Global Operation Services, End-User Informatics Job
Celgene Corporation - Summit, NJ, US
Principal Scientist
Watson Pharmaceuticals - Fort Lauderdale, FL
Associate Director, Global Production Planning & Inventory Control Job
Celgene Corporation - Basking Ridge, NJ, US
Clinical Trials Site Director
Lovelace Respiratory Research Institute - Albuquerque, NM

More Jobs >>

Events

Biomarker Applications for Improved Clinical Trial Outcomes
Nov. 15-16 — Boston
Partnerships in Clinical Trials 2012
March 4-7 — Orlando, FL
Pharmacovigilance and Risk Management Strategies 2012
January 22-25, 2012 — Arlington, Virginia
Just Released: New Trends in Preventive and Therapeutic Vaccine

More Events >>

Related Tags >> atherosclerosis

cholesterol News

Most Popular cholesterol Story

Experimental vax targets a key atherosclerosis trigger

June 9, 2010 — 2:15pm ET | By John Carroll

Researchers at the prestigious Karolinska Institute in Sweden are working on a new vaccine that could prevent the body from dispatching T cells to help ward off "bad" LDL cholesterol, inadvertently Read more...

cholesterol Press Releases

AtheroNova Rodman & Renshaw Presentation Now Online at www.AtheroNova.com
Earlier Memory Loss Tied to Cardiovascular Risks & Alzheimer’s Gene
PRESS RELEASE: Merck's "Good" Cholesterol Drug Meets Trial Goals
PRESS RELEASE: Merck Announces FDA Acceptance of NDA for CORDAPTIVE

Latest Headlines

Experimental vax targets a key atherosclerosis trigger
June 9, 2010

Paid Research Reports

Trends in mHealth and Telemedicine
The Global Aesthetic Dermatology Market Outlook
Future Directions in Regenerative Medicine
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

More Research Reports >>

THE FIERCEMARKETS NETWORK